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Highlights are mandatory for this journal. They consist of a short collection of bullet 
points that convey the core findings of the article and should be submitted in a separate 
editable file in the online submission system.  
 
Please use 'Highlights' in the file name and include 3 to 5 bullet points 
(maximum 85 characters, including spaces, per bullet point). 
 Analyses of drugs from cryptomarkets and conventional markets are compared 
 Samples include cocaine, LSD, MDMA, amphetamine, ketamine and cannabis 
resin 
 Cryptomarket-sourced drugs were less likely to be adulterated 
 The main compound detected was more likely to be higher in purity 
 Findings support theoretical predictions and perceptions of cryptomarket users 
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was published in the EMCDDA publication ‘EMCDDA Insights publication: Internet 
and Drug Markets’, 2016.  
  












INTRODUCTION: User surveys indicate that expectations of higher drug purity are a 
key reason for cryptomarket use. In 2014–2015, Spain’s NGO Energy Control 
conducted a 1-year pilot project to provide a testing service to cryptomarket drug users 
using the Transnational European Drug Information (TEDI) guidelines. In this paper, 
we present content and purity data from the trial. 
METHODS: 219 samples were analyzed by gas chromatography associated with mass 
spectrometry (GC/MS). Users were asked to report what substance they allegedly 
purchased.  
RESULTS: 40 different advertised substances were reported, although 77.6% were 
common recreational drugs (cocaine, MDMA, amphetamines, LSD, ketamine, 
cannabis). In 200 samples (91.3%), the main result of analysis matched the advertised 
substance. Where the advertised compound was detected, purity levels (m±SD) were: 
cocaine 71.6±19.4%; MDMA (crystal) 88.3±1.4%; MDMA (pills) 133.3±38.4mg; 
Amphetamine (speed) 51.3±33.9%; LSD 123.6±40.5µg; Cannabis resin THC: 
16.5±7.5% CBD: 3.4±1.5%; Ketamine 71.3±38.4%. 39.8% of cocaine samples 
contained the adulterant levamisole (11.6±8%). No adulterants were found in MDMA 
and LSD samples. 
DISCUSSION: The largest collection of test results from drug samples delivered from 
cryptomarkets are reported in this study. Most substances contained the advertised 
ingredient and most samples were of high purity. The representativeness of these results 
is unknown. 
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Studies on cryptomarkets have focused on economic and criminological aspects 
(Aldridge & Décary-Hétu, 2014; Christin, 2013) and user characteristics and 
motivations (Barratt, Ferris, & Winstock, 2014; van Hout & Bingham, 2013). Higher 
purity of substances and lower rates of adulteration, compared with ‘street’ markets, are 
reported as key reasons for their use. Most cryptomarket users who completed the 
Global Drug Survey in 2013 reported “better quality” of substances as a main reason for 
using cryptomarkets (Barratt, et al., 2014), and “concern for street drug quality” and 
“higher purity” have also been frequently reported in discussion threads in these 
marketplaces (van Hout & Bingham, 2013). Indeed, many vendors advertise that their 
products are “lab tested” and claim to have no adulterants or very high quality. It has 
also been argued that consumer feedback mechanisms available through cryptomarkets 
would result in access to higher quality drugs (Aldridge & Décary-Hétu, 2014; Christin, 
2013; Martin, 2014). 
Since 1999, Spain’s non-government organization Energy Control has offered its drug 
checking service as part of an integrated harm reduction service for recreational drug 
users. This service analyzes samples from Spanish illegal drug markets which are 
submitted by users at clubs, venues, rave parties or to Energy Control headquarters. In 
March 2014, Energy Control launched an International Drug Testing Service (IDTS) 
advertised only to cryptomarket us rs. IDTS objectives, procedures, methods and 
techniques follow the TEDI (Transnational European Drug Information) guidelines and 
methodology (TEDI, 2012). Preliminary results from the first 8 months of this service 
have been reported by Caudevilla (2016). In this paper we present data about purity and 
adulteration of samples submitted to IDTS in 1-year activity, from March 2014 to 
March 2015. We also expand the discussion to further situate the findings and the 
limitations of this unique data source. 
METHODS 
The target population were drug consumers who submitted drugs sourced through 
cryptomarkets. Information about IDTS was offered in 2 cryptomarket forums that were 
operating during the data collection period (Silk Road 2.0 and Evolution Marketplace). 
The post linked to the IDTS Energy Control web page 
(http://energycontrol.org/noticias/528-international.html) where detailed information 











about the IDTS was offered. After submitting samples for analysis, users received a 
detailed report with drug test results and specific and individualized information 
oriented to risk reduction. The cost of the service was 50 Euro payable in Bitcoin or 
through PayPal. These funds were used to cover the costs of providing the service. In 
order to maintain confidentiality we asked for no personal or socio-demographic data, 
but stamps and postmarks were used to collect information about the country of origin 
of the user (note that country of origin of the service user does not necessarily match the 
country of origin of the sample). Users were asked to report the type of substance they 
believed they were submitting for analysis. 
In the text, the term “purity” refers to the proportion of the active principle present in a 
sample compared to those of synthesis impurities, residual solvents or diluents. 
“Adulteration” refers to the addition of a component not ordinarily part of that 
substance. The identification of the specimens was performed through a combination of 
different validated analysis techniques. In order to detect the substances, determine 
purity and check for potentially toxic adulterants, a chromatographic technique was 
used: gas chromatography associated to mass spectrometry (Giné, Espinosa, & 
Vilamala, 2014). The purity of LSD was ascertained using liquid chromatography 
associated to mass spectrometry (Johansen & Jensen, 2005). Both techniques were 
performed at the Municipal Institute for Medical Research in Barcelona (IMIM – 
Hospital del Mar).  
RESULTS 
From March 2014 to March 2015 a total of 219 samples were analysed. The number of 
samples analysed increased over time: March-June 2014 (n=23), July-September 2014 
(n=50), October-December 2014 (n=57), January-March 2015 (n=89). Samples were 
submitted from Europe (n=92, 42.0%), Australia (n=57, 26.0%), United States (n=46, 
21.0%), China (n=11, 5.0%), Canada (n=7, 3.2%) and Argentina (n=6, 2.7%).  
In 200 of 219 samples (91.3%) the main result of analysis coincided with the 
information provided by the user. In the remaining 19 samples, analytical results 
revealed: (a) another drug than advertised (n=9), (b) a mixture of unexpected substances 
(n=7), or (c) the composition could not be determined with the analytical techniques 
performed (n=3). 











Table 1 shows test results from most frequently analyzed substances. In 141 of 219 
IDTS samples (64.4%) the expected substance was detected without any adulterants. No 
adulterants were detected in any substance submitted as MDMA, LSD or cannabis. In 
cocaine samples, levamisole was the most frequently detected adulterant, present in 
42.6% (42 of 103) cocaine samples (concentration: 11.7 ± 8.0%; range: 2–43%). Other 
relevant detected adulterants in cocaine samples were phenacetine 6.8% (7 of 103) 
(concentration: 28.7 ± 22.4%; range: 4–54%), caffeine 5.8% (6 of 103) (concentration:  
7.1 ± 5.7%; r: 0.3–13%), benzocaine 2.9% (3 of 103) (concentration:  25.3 ± 23.2%; 
range:  4–50%) and lidocaine 2.9% (3 of 103) (concentration:  14.7 ± 8.0%; range: 7–
23%). Caffeine was found in 40.0% (4 of 10) of amphetamine (speed) samples 
(concentration:  26.0 ± 30.8%; range:  9–72%). 
[Insert Table 1 about here] 
DISCUSSION 
Cryptomarkets offer a wide variety of products, have system of feedback and rating and 
are partially controlled by administrators. These characteristics could influence the 
quality and purity of drugs offered as suggested by predictions of criminologists and 
economists studying the mechanisms of cryptomarkets (Aldridge & Décary-Hétu, 2014; 
Christin, 2013; Martin, 2014) and the perceptions of cryptomarket users (Barratt, et al., 
2014; van Hout & Bingham, 2013). 
Some of our data are consistent with current reports and are a reflection of the global 
market. For example, results for MDMA, with high purities in crystalized form and very 
elevated dosages of MDMA in tablet form as reported here, have been recently reported 
by other harm reduction groups offering drug checking services as well (Brunt et al., 
2016). Also, frequencies of levamisole contamination in our sample are congruent with 
this widespread problem reported in the rest of the global drug market (Chang, Osterloh, 
& Thomas, 2010).  
Given broader evidence of the adulteration of conventional drugs with New 
Psychoactive Substances (NPS), the low frequency of NPS in our cryptomarket samples 
is noteworthy. Energy Control has previously identified 24 different NPS in 173 
samples that were sold as MDMA, amphetamines, ketamine or cocaine between 2009-
2012 from conventional markets (Giné et al., 2014). During 2013 and 2014, blotters 
containing 25x-NBOMe or hallucinogenic phenethylamines (DOB, DOC, DOI) in 











samples sold as LSD have been reported, sometimes associated with severe toxicity 
(Caldicott, Bright, & Barratt, 2013), but in our data we did not detect NBOMes in any 
of the samples suspected to be LSD. In our data, the vast majority of the samples were 
common recreational or prescription drugs. NPS are widely offered in cryptomarkets 
but demand appears limited (Barratt et al., 2014; Caudevilla, 2014). It is possible that 
users of NPS choose to buy them elsewhere, as their availability from easily accessible 
websites is high. An alternate explanation could be that, within the free market 
conditions provided by cryptomarkets, users prefer ‘classical’ drugs rather than 
substitutes. 
Although it would be inaccurate to formally compare our results with other data sources 
because we lack data about sample country of origin (see limitations section below), the 
purity of our sample of cryptomarket-sourced substances appears relatively high in 
comparison to other published research. In 2014, Energy Control (2015) analyzed 2938 
samples collected from the illegal Spanish drug market using the same techniques 
described in this article. In 589 alleged cocaine samples, 14% contained only cocaine, 
and the purity of samples containing cocaine was 48%. In 627 alleged crystal MDMA 
samples, 84% of samples contained only MDMA, and the purity detected was 74%. In 
359 alleged MDMA pills, 69% of samples contained only MDMA, and the MDMA 
concentration per pill was 114mg. Another European data source used police seizure 
data to estimate the purity of cocaine (interquartile range 33–50%), amphetamine (IQR 
9–19%), and MDMA pills (IQR 77–98 mg) (EMCDDA, 2015). Taking just the example 
of cocaine for which we have the greatest number of samples (n=103), the purity of 
cryptomarket cocaine samples (71.6%) appears relatively high compared with the 
Spanish illicit drug market (48%) and the broader European seizures (interquartile range 
33–50%). Cryptomarket cocaine samples also appear to be less likely to be adulterated 
(51.5% only contained cocaine) compared with samples from the Spanish illicit drug 
markets (14% only contained cocaine).  Access to a matched comparison group is 
needed to reliably test for differences in adulteration and purity levels. 
This study has a number of limitations which should be considered when interpreting 
our results. While the invitation for cryptomarket users to access the service was only 
actively promoted by Energy Control within cryptomarket forums, a Google search of 
the URL found that it was posted to other drug websites, including illicit drug 
discussion groups, steroid discussion groups, and other social discussion sites, therefore 











we cannot guarantee that all of the drugs tested through this service were bought 
through cryptomarkets. It is not possible for us to ascertain the country of origin of the 
drugs submitted for testing, although this limitation is also present when analyzing 
samples from conventional markets. It was also not possible for us to compare the 
cryptomarket results with fully comparable data from conventional drug markets, due to 
lack of information about country of origin. Additionally, our sample is not necessarily 
a representative sample of cryptomarket drugs more broadly, and that for all drugs 
except cocaine, our estimates rely on a small number of samples, which may limit their 
reliability. To address these limitations, our service will add additional items for service 
users to complete asking them whether their sample was sourced through cryptomarkets 
and the suspected country of origin of the sample. 
It is also possible that some of the samples have been submitted to analysis by dealers to 
use test reports as a proof for their “good quality products”. This was a major concern 
for us as our service is conceived as a harm reduction tool for drug consumers and not a 
“quality control guarantee” for vendors. As part of our work in this project we 
conducted weekly monitoring of markets and forums during the study (Silk Road 2.0 
and Evolution Marketplace) and we did not detect any vendor using our information in 
this sense. We have been aware in three occasions that some users have started up 
crowdfunding initiatives to submit samples and publish results (for example see: 
http://avengerfxkkmt2a6.onion/). In these cases we have asked that the following notice 
be posted—“the test result is only valid for the submitted sample and it is not a 
guarantee of vendor or market”—and this has occurred in all cases. 
On the whole, the main substances analyzed by IDTS are the same as the ones used in 
recreational settings: MDMA, amphetamines and cocaine. Each of these substances 
varies greatly with regard to their levels of purity and their adulterant percentages. For 
users, this means not only dealing with the risks of the substance but also dealing 
effectively with the risks associated with its adulterants. Some of the analyzed 
substances (penthobarbital, acetylfentanil, butyrfentanil and scopolamine) and some of 
the adulterants detected (levamisole and phenacetin) pose a greater overdose risk than 
better-known substances and expose users to other potentially life-threatening situations 
(McIntyre et al., 2015). Our data suggest that the hypothesis of higher purities of 
substances in cryptomarkets is plausible but future papers utilizing a larger sample size 
and comparisons with other sources of information are needed to confirm this. In this 











complex environment of unregulated supply, the only way to learn about the actual 
composition of these substances is to have them properly tested by a drug testing 
service. Furthermore, the introduction of a drug testing service within cryptomarkets is 
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Table 1: Advertised substance and purities in samples from International Drug Testing Service (March 2014 – March 2015) 
Advertised 
substance a 
n Substance detected Purity of advertised substance b 
Only the advertised 
substance 
Advertised  substance 
combined with other 
substances 
Does not contain 
the advertised 
substance 
Mean ± SD Range 
Cocaine 103 51.5% (53/103) 46.6% (48/103) 1.9% (2/103) 71.6 ± 19.4% 5-99% 
LSD 15 100.0% (15/15) 0 0 123.6 ± 40.5µg  53-195µg 
MDMA crystal 13  100.0% (13/13) 0 0 88.3 ± 1.4% 76-99% 
MDMA pills 11 100.0% (11/11) 0 0 133.3 ± 38.4mg 83-188mg 
Amphetamine  10 40.0% (4/10) 60.0% (6/10) 0 51.3 ± 33.9% 10-98% 
Ketamine 6 50.0% (3/6) 33.3% (2/6) 16.7% (1/6) 71.3 ± 38.4% 27-95% 
Cannabis 
resin 
5 100.0% (5/5) 0 0 THC: 16.5 ± 7.5% 
CBD: 3.4 ± 1.5% 
THC: 9.1-16.4% 
CBD: 1.6-5.3% 
aOnly advertised substances with 5 or more samples are shown. Other advertised substances analyzed were 5F-PB-22, mephedrone, MDA (n=4), 
methamphetamine, alprazolam (n=3), clonazepam, ephedrine, midazolam, modafinil, mescaline, DMT, 2C-B, 2C-E, butyrfentanil, DOB, DOET, DOM, DON, 
DXM, ethylphenidate, flubromazepam, kratom, methylone, penthedrone, penthobarbital, nimetazepam, 2-MeO-diphenidine, 3-fluorophemetrazine, acetyl 
fentanyl, alfa-PVP, benzocaine, scopolamine, AKB-48, XLR-11 (n=1). 
 b  Purities have been calculated using any sample containing advertised substances (both alone and in combination).  
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